雷公藤多苷联合缬沙坦治疗慢性肾小球肾炎合并高血压患者的临床疗效及对炎症因子的影响

摘要

Objective To explore the clinical curative effect of combination of Tripterygium glycosides and Valsartan on chronic Glomerulonephritis complication with hypertension and the influence on inflammatory cytokines.Methods 90 cases of patients with chronic glomerulonephritis complication with hypertension in our hospital were selected from January 2015 to January 2016,To adopt randomized single blind controlled design methods,were divided into the treatment group Tripterygium glycosides combined with Valsartan,and the control group Tripterygium glycosides,each group were 45 cases,continuous medication for 24 weeks.Before and after treatment respectively observe the changes in blood pressure,24h urinary protein,endogenous creatinine clearance rate(Ccr),blood urea nitrogen(BUN),serum creatinine(Scr),glomerular filtration rate(GFR),inflammatory cytokines such as tumor necrosis factor-α,hypersensitive C-reactive protein,interleukin-6 as reference indicators.Results All the patients were observed for 24 weeks,no adverse effects were found.The effective rate of the treatment group was 95.55%,significantly higher than 75.55%of the control group(P<0.05).After treatment,systolic blood pressure(SBP),diastole blood pressure(DBP),24h urinary protein,SCr and BUN were all decrease,while Ccr and GFR were improved,and inflammatory cytokines such as tumor necrosis factor-α,hypersensitive C-reactive protein,interleukin-6 were reduced in the treatment group and the control group,the difference was statistically significant(P<0.05).Compared with the control group,blood pressure,24h urinary protein,Ccr, Scr,GFR,TNF-α、hs-CRP were improved in the treatment group(P<0.05).Conclusion Tripterygium glycosides combined with Valsartan treatment has good clinical curative effect,It can effectively relieve the symptom of chronic Glomerulonephritis complication with hypertension.%目的：观察雷公藤多苷联合缬沙坦治疗高血压合并慢性肾小球肾炎患者的临床疗效及对炎症因子的影响。方法选取2015年1月～2016年1月湖州市中心医院收治的慢性肾小球肾炎合并高血压患者90例。釆用随机单盲对照法将其分为实验组（雷公藤多苷联合缬沙坦）和对照组（缬沙坦），每组各45例，连续用药24w。治疗前后分别观察血压变化、24 h尿蛋白定量、内生肌酐清除率（ endogenous creatinine clearance rate，Ccr）、尿素氮（ blood urea nitrogen，BUN）、血肌酐（ serum creatinine，Scr），并估算肾小球滤过率（glomerular filtration rate，GFR）及炎症因子：肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α）、超敏C反应蛋白（hypersensitive C-reactive protein，hs-CRP）、白介素-6（interleukin-6，IL-6）水平变化情况。结果所有患者均顺利完成24w的治疗，未发现明显不良反应。实验组总有效率为95.55％，明显高于对照组的75.55％（ P＜0.05）。实验组与对照组的平均收缩压（ systolic blood pressure， SBP）、平均舒张压（diastole blood pressure，DBP）、24h尿蛋白定量、SCr及BUN较治疗前均明显下降，Ccr、GFR明显上升，炎性因子TNF-α、hs-CRP、IL-6水平较均有显著降低，差异具有统计学意义（P＜0.05）。实验组在改善血压、24h尿蛋白定量、SCr、Ccr、GFR，调节血清中炎性因子TNF-α、hs-CRP水平方面要优于缬沙坦对照组（ P＜0.05）。结论慢性肾小球肾炎合并高血压患者采用雷公藤多苷联合缬沙坦治疗有较好的临床疗效，可有效改善病情。